Fundraising FoxAtlas Venture — 2018 Investments
8 investments dated 2018 · listed companies and verified rows first · show all
Cadent Therapeutics was a Cambridge, Massachusetts-based neuroscience company developing clinical-stage therapies for neuropsychiatric disorders including schizophrenia, movement disorders, and treatment-resistant depression.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Co-investorsQiming Venture Partners USASlater Technology FundAccess IndustriesClal Biotechnology IndustriesCowen Healthcare InvestmentsNovartis Institute for Biomedical Research+1 more
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsForesite CapitalWellington ManagementCasdin CapitalDeerfield Management CompanyF-Prime CapitalFidelity Investments+1 more
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsB Capital GroupB4 CapitalMRL Ventures FundPivotal Life SciencesSofinnova PartnersSolasta Ventures+2 more
.jpeg){kind=logo}
Plastiq enables businesses to pay vendors using credit cards while vendors receive payments via wire, ACH, check, or other methods, combined with embedded payment processing and card acceptance solutions for merchant transactions.
FintechSan Francisco, US
Eliot Buchanan(Executive Officer, Director)inDaniel Choi(Executive Officer)inGeoffrey Willison(Executive Officer)inMichail Medvinsky(Executive Officer)in
BoardRyan Moore(Director)Jeffrey Bussgang(Director)in
Co-investorsAcorn Pacific VenturesBling CapitalFlybridge Capital PartnersParade VenturesSocii CapitalAccomplice+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.